Article
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations
1 Jun 1999
Abstract excerpt
The increasing resistance of falciparum malaria to common antimalarial drugs has renewed interest in the compound proguanil normally metabolized to cycloguanil, a strong dihydrofolate reductase inhibitor, via the cytochrome P450 isozyme CYP2C19. The relationship between CYP2C19 genotypes and proguanil metabolism was therefore studied in 100 uncomplicated malaria patients on Malakula island in Vanuatu, where a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
